troglitazone has been researched along with Hemangiosarcoma in 8 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Hemangiosarcoma: A rare malignant neoplasm characterized by rapidly proliferating, extensively infiltrating, anaplastic cells derived from blood vessels and lining irregular blood-filled or lumpy spaces. (Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine the tumor-promoting effect of troglitazone (TRG), a novel thiazolidinedione insulin-sensitizing agent, on splenic hemangiosarcomas in rasH2 mice, histopathological and molecular analyses were performed in the spleen of female rasH2 mice fed a diet containing 6,000 or 0 ppm TRG for 16 weeks after 1,000 or 0 mg/kg urethane (UR) initiation." | 7.74 | Extremely weak tumor-promoting effect of troglitazone on splenic hemangiosarcomas in rasH2 mice induced by urethane. ( Dewa, Y; Hasumi, K; Jin, M; Matsumoto, S; Mitsumori, K; Nishimura, J; Saekusa, Y, 2008) |
| "To examine the tumor-promoting effect of troglitazone (TRG), a novel thiazolidinedione insulin-sensitizing agent, on splenic hemangiosarcomas in rasH2 mice, histopathological and molecular analyses were performed in the spleen of female rasH2 mice fed a diet containing 6,000 or 0 ppm TRG for 16 weeks after 1,000 or 0 mg/kg urethane (UR) initiation." | 3.74 | Extremely weak tumor-promoting effect of troglitazone on splenic hemangiosarcomas in rasH2 mice induced by urethane. ( Dewa, Y; Hasumi, K; Jin, M; Matsumoto, S; Mitsumori, K; Nishimura, J; Saekusa, Y, 2008) |
| "Troglitazone was cytotoxic both to human dermal microvascular endothelial cells (HMEC1) and mouse mammary fat pad microvascular endothelial cells (MFP MVEC) at high concentrations." | 1.35 | Effects of the PPARgamma agonist troglitazone on endothelial cells in vivo and in vitro: differences between human and mouse. ( Arnold, LL; Cohen, SM; Han, HY; Kakiuchi-Kiyota, S; Nascimento, M; Pennington, KL; Singh, RK; Suzuki, S; Varney, ML; Vetro, JA, 2009) |
| "The incidence of hepatocellular carcinoma was increased in female mice at 800 mg/kg." | 1.31 | Rodent carcinogenicity with the thiazolidinedione antidiabetic agent troglitazone. ( de la Iglesia, FA; Dethloff, LA; Gough, AW; Herman, JR; Masuda, H; McGuire, EJ; Parker, RF; Walsh, KM, 2002) |
| "Hemangiosarcomasare uncommon malignant endothelial cell tumors in humans and experimental animal species." | 1.30 | Spontaneous and thiazolidinedione-induced B6C3F1 mouse hemangiosarcomas exhibit low ras oncogene mutation frequencies. ( Bleavins, MR; de la Iglesia, FA; Duddy, SK; Gorospe, SM, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cook, JC | 1 |
| Obert, LA | 1 |
| Koza-Taylor, P | 2 |
| Coskran, TM | 1 |
| Opsahl, AC | 1 |
| Ziemek, D | 1 |
| Roy, M | 1 |
| Qian, J | 1 |
| Lawton, MP | 1 |
| Criswell, KA | 1 |
| Kakiuchi-Kiyota, S | 2 |
| Vetro, JA | 1 |
| Suzuki, S | 2 |
| Varney, ML | 1 |
| Han, HY | 1 |
| Nascimento, M | 1 |
| Pennington, KL | 2 |
| Arnold, LL | 2 |
| Singh, RK | 1 |
| Cohen, SM | 2 |
| Yokohira, M | 1 |
| Varney, M | 1 |
| Jin, M | 2 |
| Takahashi, M | 1 |
| Moto, M | 1 |
| Muguruma, M | 1 |
| Ito, K | 1 |
| Watanabe, K | 1 |
| Kenmochi, Y | 1 |
| Kono, T | 1 |
| Hasumi, K | 2 |
| Mitsumori, K | 2 |
| Matsumoto, S | 1 |
| Dewa, Y | 1 |
| Nishimura, J | 1 |
| Saekusa, Y | 1 |
| Duddy, SK | 2 |
| Parker, RF | 2 |
| Bleavins, MR | 2 |
| Gough, AW | 2 |
| Rowse, PE | 1 |
| Gorospe, S | 1 |
| Dethloff, LA | 2 |
| de la Iglesia, FA | 3 |
| Gorospe, SM | 1 |
| Herman, JR | 1 |
| McGuire, EJ | 1 |
| Walsh, KM | 1 |
| Masuda, H | 1 |
8 other studies available for troglitazone and Hemangiosarcoma
| Article | Year |
|---|---|
From the Cover: Fenretinide, Troglitazone, and Elmiron Add to Weight of Evidence Support for Hemangiosarcoma Mode-of-Action From Studies in Mice.
Topics: Animals; Cell Hypoxia; Cell Proliferation; Dose-Response Relationship, Drug; Endothelial Cells; Fenr | 2018 |
Effects of the PPARgamma agonist troglitazone on endothelial cells in vivo and in vitro: differences between human and mouse.
Topics: Adipose Tissue; Animals; Carcinogenicity Tests; Cell Proliferation; Cell Survival; Cells, Cultured; | 2009 |
Evaluation of direct and indirect effects of the PPARĪ³ agonist troglitazone on mouse endothelial cell proliferation.
Topics: Adipose Tissue; Animals; Antineoplastic Agents; Body Weight; Cell Growth Processes; Cell Hypoxia; Ce | 2011 |
Carcinogenic susceptibility of rasH2 mice to troglitazone.
Topics: Adipose Tissue, Brown; Administration, Oral; Animals; Carcinogenicity Tests; Chromans; Dose-Response | 2007 |
Extremely weak tumor-promoting effect of troglitazone on splenic hemangiosarcomas in rasH2 mice induced by urethane.
Topics: Angiogenic Proteins; Animals; Body Weight; Carcinogens; Cell Proliferation; Chromans; Female; Gene E | 2008 |
p53 is not inactivated in B6C3F1 mouse vascular tumors arising spontaneously or associated with long-term administration of the thiazolidinedione troglitazone.
Topics: Animals; Antioxidants; Chromans; DNA, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene | 1999 |
Spontaneous and thiazolidinedione-induced B6C3F1 mouse hemangiosarcomas exhibit low ras oncogene mutation frequencies.
Topics: Animals; Carcinogens; Chromans; DNA, Neoplasm; Evolution, Molecular; Female; Genes, ras; Hemangiosar | 1999 |
Rodent carcinogenicity with the thiazolidinedione antidiabetic agent troglitazone.
Topics: Adipose Tissue, Brown; Administration, Oral; Animals; Area Under Curve; Bone Marrow; Carcinogenicity | 2002 |